COVID-19 Information Center

Novartis is responding to COVID-19 with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.

Novartis response to COVID-19

In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.

Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19

Sandoz initiates program supporting HCPs globally

Educational program to share knowledge and best practice on COVID-19 among HCPs globally.

International Rescue Committee announces $1 million contribution from Novartis in support of COVID-19 response in East Africa

Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia

April 28, 2020

Novartis announces flexible return to office and on-site field activities, starting May 11, 2020

April 23, 2020

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

April 20, 2020

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

April 17, 2020

News Feed

COVID-19: A visual tour of scientific strategies for combating coronavirus

Researchers around the world are collaborating to provide solutions to immediate and future challenges.

Guidance

Woman looking at an Ipad in a waiting room

Patients and Caregivers

Novartis is working to ensure supply of our medicines, enhance virtual services, protect the integrity of clinical trials and support patient organizations during the COVID-19 pandemic.

Learn More

Healthcare Professionals

Novartis is working closely with healthcare professionals during the coronavirus disease pandemic. We are embracing new ways of working and have rapidly scaled up multichannel engagement.

Learn More

Investors and Shareholders

Novartis is regularly updating our Investor and Shareholder communities on the impact of COVID-19 and our response.

Latest Investor Updates (Q1 2020 Results)

Job candidates

Novartis is supporting candidates during the COVID-19 outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.

Learn More

Suppliers

Novartis is providing suppliers with recommended good practices guidance during the COVID-19 pandemic based on the most up-to-date World Health Organization (WHO) technical information.

Download the COVID-19 Guidance for Third Parties (PDF 0.3 MB)

COVID-19 country resources

Novartis provides country-specific information about coronavirus disease (COVID-19) in local languages.

Learn More

Clinical trials

SARS-CoV-2 is the virus that causes COVID-19

COVID-19: Clinical trial comes together in weeks to address coronavirus

Researchers race to put hydroxychloroquine to the test in a large study.

Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

Learn More

Novartis COVID-19 Response Fund

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

Learn More

Research and collaborations

COVID-19 Therapeutics Accelerator

Novartis has joined the accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard

Learn More

Transmission electron micrograph of SARS-CoV-2 virus particles

ACTIV partnership

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.

Innovative Medicines Initiative (IMI)

Novartis is part of a consortium engaging with the Innovative Medicines Initiative (IMI) on their COVID-19 directed efforts.

About IMI

EFPIA call for therapeutic treatments R&D

Novartis is making available several compounds from our libraries that are considered suitable for in vitro antiviral testing

Learn More

Perspectives

Joining Monocle’s The Big Interview Podcast

Novartis CEO Vas Narasimhan joins Monocle’s editor in chief, Tyler Brûlé to talk about crisis management, the vaccine race and the future of work during episode 114 of The Big Interview.

Listen to podcast